Actinium Pharmaceuticals Stock Current Valuation
| ATNM Stock | USD 1.34 0.07 4.96% |
Valuation analysis of Actinium Pharmaceuticals helps investors to measure Actinium Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 3rd of December 2024, Enterprise Value is likely to grow to about 77.2 M, while Enterprise Value Over EBITDA is likely to drop (1.24). Fundamental drivers impacting Actinium Pharmaceuticals' valuation include:
Price Book 1.1757 | Enterprise Value -32 M | Enterprise Value Ebitda (3.62) | Price Sales 543.0397 | Forward PE 6.8399 |
Undervalued
Today
Please note that Actinium Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Actinium Pharmaceuticals is based on 3 months time horizon. Increasing Actinium Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Actinium stock is determined by what a typical buyer is willing to pay for full or partial control of Actinium Pharmaceuticals. Since Actinium Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Actinium Stock. However, Actinium Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.34 | Real 7.95 | Target 27.6 | Hype 1.43 | Naive 1.45 |
The intrinsic value of Actinium Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Actinium Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Actinium Pharmaceuticals helps investors to forecast how Actinium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Actinium Pharmaceuticals more accurately as focusing exclusively on Actinium Pharmaceuticals' fundamentals will not take into account other important factors: Actinium Pharmaceuticals Company Current Valuation Analysis
Actinium Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Actinium Pharmaceuticals Current Valuation | (32.03 M) |
Most of Actinium Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Actinium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Actinium Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Actinium Pharmaceuticals is extremely important. It helps to project a fair market value of Actinium Stock properly, considering its historical fundamentals such as Current Valuation. Since Actinium Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actinium Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actinium Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Actinium Current Valuation Historical Pattern
Today, most investors in Actinium Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Actinium Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Actinium Pharmaceuticals current valuation as a starting point in their analysis.
Actinium Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Actinium Pharmaceuticals has a Current Valuation of (32.03 Million). This is 100.22% lower than that of the Biotechnology sector and 100.69% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.19% higher than that of the company.
Actinium Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actinium Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actinium Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Actinium Pharmaceuticals by comparing valuation metrics of similar companies.Actinium Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Actinium Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Actinium Pharmaceuticals from analyzing Actinium Pharmaceuticals' financial statements. These drivers represent accounts that assess Actinium Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Actinium Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 32.5M | 94.6M | 123.6M | 257.1M | 135.1M | 86.5M | |
| Enterprise Value | 24.7M | 31.8M | 46.1M | 150.8M | 60.6M | 77.2M |
Actinium Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (576.65) % | ||||
| Current Valuation | (32.03 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 30.10 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 543.04 X | ||||
| Revenue | 81 K | ||||
| Gross Profit | 1.03 M | ||||
| EBITDA | (51.13 M) | ||||
| Net Income | (48.82 M) | ||||
| Cash And Equivalents | 116.33 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 2.11 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 18.83 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (47.34 M) | ||||
| Short Ratio | 5.72 X | ||||
| Earnings Per Share | (1.36) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 49 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 43.99 M | ||||
| Total Asset | 81.44 M | ||||
| Retained Earnings | (337.58 M) | ||||
| Working Capital | 69.77 M | ||||
| Current Asset | 26.48 M | ||||
| Current Liabilities | 4.61 M | ||||
| Net Asset | 81.44 M |
About Actinium Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actinium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actinium Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actinium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Actinium Pharmaceuticals Piotroski F Score and Actinium Pharmaceuticals Altman Z Score analysis. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.